Acute Respiratory Distress Syndrome

A life-threatening acute respiratory failure syndrome characterised by diffuse alveolar damage and bilateral infiltrates, with in-hospital mortality of 27–45%. Up to 40% of cases remain clinically unrecognised on the first day of presentation.

About Acute Respiratory Distress Syndrome

In numbers

Approximately 190,000 US cases per year; incidence approximately 58–60 per 100,000 annually. In-hospital mortality ranges from 27% (mild) to 45% (severe) on Berlin criteria.
ARDS affects all age groups; peak incidence in adults aged 40–70 years, with substantially higher mortality in older and immunocompromised patients.
An estimated 40% of ARDS cases are not clinically recognised within the first 24 hours, delaying ventilation escalation and increasing preventable mortality.

Special details

ARDS incidence is substantially higher in low- and middle-income countries, where lung-protective ventilation and ICU resource access remains limited.
Precipitating causes include pneumonia (most common globally), sepsis, trauma, and aspiration — proportions vary across care settings and geographies.
US data documents racial disparities in ARDS outcomes, with Black patients experiencing higher incidence and worse short-term outcomes.

Signs and symptoms of Acute Respiratory Distress Syndrome

ARDS develops within 7 days of a clinical insult. Around 40% of cases are not clinically recognised on Day 1 — and conventional monitoring identifies pneumonia progression only 2–6 hours ahead of deterioration.

$Severe hypoxaemia refractory to standard supplemental oxygen$

Severe hypoxaemia refractory to standard supplemental oxygen

With bilateral infiltrates on chest X-ray or CT not explained by cardiac failure.

Tachypnoea and dyspnoea at rest

Typically developing within 24–72 hours of a precipitating cause such as pneumonia, sepsis, or aspiration.

Acute respiratory failure necessitating mechanical ventilation

With low lung compliance requiring lung-protective ventilation to prevent ventilator-induced lung injury.

Cardiogenic pulmonary oedema is excluded by echocardiography

Bilateral infiltrates must not be fully explained by fluid overload to meet ARDS criteria.

Systemic features of the precipitating cause

Fever, hypotension, altered consciousness — often dominate the clinical picture, delaying recognition of ARDS criteria.

Key challenges from product development to launch

Strategy and Business

The wrong disease or indication selected for investment
Indications tackled in the wrong order due to shaky success estimates
R&D returns slipping below the cost of capital

Clinical Development

Trials delayed by low patient recruitment
High screen-failure rates that raise trial cost
Mixed cohorts that make the signals difficult to detect

HEOR, Access & Value

A value case that arrives too late or is underdeveloped
Eligible population under-counted, budget-impact case unsubstantiated
Approved by the regulator, delayed at HTA

Medical Affairs

Fragmented, differently-coded healthcare data
Diagnostic delay that is long and unequal
No shared evidence base across functions

Launch and Commercial

Launch planned without a view of the number of findable patients
Targeting too broad a population slows early uptake
RWE started too late to build the case

How Volv Global Helps

Strategy and Business

Pipeline mistakes compound from the earliest decisions: wrong indication, indications tackled in the wrong order, capital deployed where returns already trail the cost of capital.

inTrigue

Finds the true reachable population per candidate, so indication choices rest on evidence.

volv.global/finding-patients

inFlow

Adds probability-of-success and outcome evidence to help prioritise the pipeline.

volv.global/predict-patient-outcomes

Clinical Development

When patients cannot be found, recruitment stalls and the burn rate climbs. High screen failure rates add to the drain, and a mixed cohort makes the results harder to interpret.

inTrigue

Finds the undiagnosed and mis-coded patients conventional feasibility misses, widening the recruitable pool.

volv.global/finding-patients

inCare

Surfaces diagnosed-but-hidden, trial-eligible patients already in the data, so sites enrol faster.

volv.global/stratifying-patient-cohorts

inFlow

Predicts who will progress or respond, enriching the cohort so the signal is not diluted.

volv.global/predict-patient-outcomes

HEOR, Access & Value

Thin or late evidence lets payers restrict access or cut the price. A poorly sized population exposes the budget case, and HTA demands more than the regulator.

inFlow

Generates the real-world evidence and outcomes payers ask for, ahead of the submission deadline.

volv.global/predict-patient-outcomes

inTrigue

Finds the undiagnosed patients missing from the count, so the eligible population holds up under scrutiny.

volv.global/finding-patients

inCare

Surfaces the diagnosed-but-eligible patients who expand the eligible population count.

volv.global/stratifying-patient-cohorts

Medical Affairs

Fragmented data must be built market by market, slowing decisions. Time to correct diagnosis varies by who the patient is and where they receive care.

inTrigue

Works across fragmented, differently-coded data by design, so insight holds up country to country without a rebuild.

volv.global/finding-patients

inAdvance

Detects patients ahead of typical diagnosis, closing the gap in awareness and pathway that drives unequal delay.

volv.global/earlier-detection

Launch and Commercial

A launch without a view of findable patients is poorly resourced from day one. Targeting too broad a population slows early uptake, and late real-world evidence means the access dossier goes in rushed.